Explainer: What does new data say about Gilead's experimental coronavirus drug?
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Saturday
February 04, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SATURDAY, FEBRUARY 04, 2023
Explainer: What does new data say about Gilead's experimental coronavirus drug?

Coronavirus chronicle

Reuters
30 April, 2020, 09:20 am
Last modified: 30 April, 2020, 09:29 am

Related News

  • Hong Kong says 'hello' to woo back visitors after Covid
  • US to end Covid-19 emergency declarations on 11 May
  • Covid remains a public health emergency, says WHO
  • Holiday trips within China surge after lifting of Covid curbs
  • India launches world’s 1st intranasal Covid vaccine

Explainer: What does new data say about Gilead's experimental coronavirus drug?

New clinical data on Gilead Sciences Inc’s experimental antiviral drug remdesivir has raised hopes it might be an effective treatment for the novel coronavirus

Reuters
30 April, 2020, 09:20 am
Last modified: 30 April, 2020, 09:29 am
An ampule of Ebola drug remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (Covid-19) continues/ Reuters
An ampule of Ebola drug remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (Covid-19) continues/ Reuters

New clinical data on Gilead Sciences Inc's experimental antiviral drug remdesivir has raised hopes it might be an effective treatment for the novel coronavirus that has infected more than 3 million people and killed over 225,000 worldwide.

On Wednesday, partial data from three different trials of the drug were released, creating both excitement and confusion.

Much analysis and more studies are needed to understand which Covid-19 patients are most likely to benefit from the drug if it is deemed effective, under what circumstance it should be given, and whether it has any impact on the death rate.

The following is what we do know about the latest three studies.

What We Know About The US Government's Trial Results

The US National Institute of Allergy and Infectious Diseases (NIAID) released preliminary results from a large randomized trial suggesting hospitalized patients with Covid-19 and lung complications recovered 31% faster with remdesivir than with a placebo.

In the 1,063-patient trial, the time it took for half the patients to recover was 11 days with remdesivir versus 15 days for patients in the placebo group.

The data also suggest a possible survival benefit with remdesivir, although the difference was not statistically significant, meaning it might have been due to chance and not Gilead's drug.

Comparing the drug to a placebo should give researchers definitive answers about remdesivir's effect on the illness.

While the study did meet its primary goal, the promising NIAID data are from an interim analysis. The trial's final results will likely not be known until sometime next month.

What We Know About Results Of A Separate Trial Led By Gilead

Gilead reported that in severe Covid-19 cases, five days of treatment with remdesivir was as good as 10 days of treatment, so if the drug is ultimately deemed to be beneficial, there will be more of it to go around. It could also lessen the eventual cost of treatment.

In the study, most patients who received the 5-day regimen were considered "improved" after 10 days. Those who received a 10-day course of therapy showed improvement after 11 days.

After two weeks, more than half the patients in both groups had been discharged from the hospital, and 64.5% in the 5-day treatment group and 53.8% in the 10-day treatment group had recovered.

Data from the study also suggest that starting remdesivir therapy sooner after symptoms develop might help patients with severe Covid-19 get out of the hospital faster than those who began therapy later in the course of the illness.

However, this study did not have a control group, so we do not know whether patients in the two treatment groups would have fared any better than patients not treated with remdesivir.

What We Know About The Trial Results From China

In a randomized study of adults hospitalized for severe Covid-19 in Wuhan, China - the original epicenter of the pandemic - the 158 patients who received remdesivir did not improve any faster than the 79 patients in a control group who received a placebo. The drug also failed to lower the amount of virus in the body or the risk of death.

However, because the outbreak in China was brought under control, researchers had trouble enrolling enough patients in their trial to produce statistically significant data, so the results are not conclusive. The study report underwent peer review before publication in The Lancet.

One Medical Expert's Take On The Trials

"We have these three studies coming out on the same day and they're all different," said Holly Fernandez Lynch, an assistant professor of medical ethics at the University of Pennsylvania, who was not involved in the studies.

"We have the NIAID results going one direction. We have the China results going another direction. Then we've got this five- versus 10-day trial that can't be a tie breaker because it's not controlled.

"Of the three, I do think the NIAID results are going to be the most reliable, but until we actually see the results as opposed to the summary, it's hard to say."

Top News

remdesivir / Gilead coronavirus drug / Coronavirus / COVID-19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Is the IMF to blame for growing pressure on your wallet?
    Is the IMF to blame for growing pressure on your wallet?
  • Dr Salehuddin Ahmed. Illustration: TBS
    Reforms in banking must to sustain financial sector
  • With only one government run specialised cancer hospital in the capital — the National Institute Of Cancer Research and Hospital (NICRH) in Mohakhali — patients have no option but to resort to private hospitals. Photo: Noor A Alam.
    Cancer care: Medical treatment and beyond

MOST VIEWED

  • Tourists ride a tour bus in Hong Kong, China October 25, 2019. REUTERS/Ammar Awad
    Hong Kong says 'hello' to woo back visitors after Covid
  • People wearing face masks following the coronavirus disease (Covid-19) outbreak are seen at Beijing Daxing International Airport in Beijing, China July 23, 2020. Photo:Reuters
    Pandemic to paradise: Chinese tourists return to Bali after three years
  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs

Related News

  • Hong Kong says 'hello' to woo back visitors after Covid
  • US to end Covid-19 emergency declarations on 11 May
  • Covid remains a public health emergency, says WHO
  • Holiday trips within China surge after lifting of Covid curbs
  • India launches world’s 1st intranasal Covid vaccine

Features

Photo: Noor-A-Alam

Say 'Salud' before your salad main course

2h | Food
With only one government run specialised cancer hospital in the capital — the National Institute Of Cancer Research and Hospital (NICRH) in Mohakhali — patients have no option but to resort to private hospitals. Photo: Noor A Alam.

Cancer care: Medical treatment and beyond

3h | Panorama
Andy Mukherjee. Sketch: TBS

What makes India's billionaires' support special for Adani

1d | Panorama
Photo: Rejaul Hafiz Rahi

A jackal farewell

1d | Earth

More Videos from TBS

A proper price formula can help investors to plan big

A proper price formula can help investors to plan big

1d | TBS Round Table
Rumors about Sarika that everyone thinks are true

Rumors about Sarika that everyone thinks are true

1d | TBS Entertainment
Mugging rife in Tejgaon, murder in Wari

Mugging rife in Tejgaon, murder in Wari

1d | TBS Current Affairs
What secrets are hidden behind Adani's wealth?

What secrets are hidden behind Adani's wealth?

1d | TBS Stories

Most Read

1
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

2
Photo: Collected
Energy

8 Ctg power plants out of production

3
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

4
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

5
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

6
Belal Ahmed new acting chairman of SIBL
Banking

Belal Ahmed new acting chairman of SIBL

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]